Synthesis of Hsp90 inhibitor dimers as potential antitumor agents

被引:13
|
作者
Muranaka, Kazuhiro [1 ]
Sano, Akiko [2 ]
Ichikawa, Satoshi [1 ]
Matsuda, Akira [1 ]
机构
[1] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan
[2] Taiho Pharmaceut Co Ltd, Hanno Res Ctr, Discovery & Dev Lab 1, Hannou 3578527, Japan
关键词
heat shock protein; Hsp90; PU3; anticancer; structure-based drug design;
D O I
10.1016/j.bmc.2008.04.070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Structure-based drug design was used to systematically synthesize PU3-dimers. The cytotoxicity of PU3 dimers 6 against breast cancer cell lines was evaluated, and their potency increased as the length of the bridging linker increased. Among the compounds tested, 6e with a C-20 linker was the most potent and exhibited a 20- to 30-fold increase in activity compared with that of the parent compound 5. Western blot analyses of the cell lysates treated with 6c revealed that 6c resulted in the concentration-dependent degradation of the Hsp90 client protein Her2, which is consistent with other Hsp90 inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5862 / 5870
页数:9
相关论文
共 50 条
  • [1] Efficient synthesis of Hsp90 inhibitor dimers as potential antitumor agents
    Sekiguchi, Hironori
    Muranaka, Kazuhiro
    Osada, Akiko
    Ichikawa, Satoshi
    Matsuda, Akira
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (15) : 5732 - 5737
  • [2] Design and Synthesis of an Hsp90 and HDAC Dual Inhibitor as Antitumor Agent
    Wu, Jiyong
    Wang, Dongbo
    Nie, Jing
    Zhang, Di
    Sun, Lei
    Kan, Shifeng
    Xu, Wei
    LETTERS IN DRUG DESIGN & DISCOVERY, 2023, 20 (06) : 619 - 627
  • [3] ALTERNATE SYNTHESIS OF HSP90 INHIBITOR AT13387
    Liang, Cuirong
    Gu, Lingling
    Yang, Yang
    Chen, Xin
    SYNTHETIC COMMUNICATIONS, 2014, 44 (16) : 2416 - 2425
  • [4] Recent progress and structural insights of potential Hsp90 inhibitors as anticancer agents
    Singh, Aastha
    Maity, Subhadip
    Devi, Priya
    Rai, Aman
    Asati, Vivek
    MOLECULAR DIVERSITY, 2025,
  • [5] Discovery of a Novel Hsp90 Inhibitor by Fragment Linking
    Barker, John J.
    Barker, Oliver
    Courtney, Stephen M.
    Gardiner, Mihaly
    Hesterkamp, Thomas
    Ichihara, Osamu
    Mather, Owen
    Montalbetti, Christian A. G. N.
    Mueller, Annett
    Varasi, Mario
    Whittaker, Mark
    Yarnold, Christopher J.
    CHEMMEDCHEM, 2010, 5 (10) : 1697 - 1700
  • [6] Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90
    Gaonkar, Roopa
    Shiralgi, Yallappa
    Lakkappa, Dhananjaya B.
    Hegde, Gurumurthy
    TOXICOLOGY REPORTS, 2018, 5 : 489 - 496
  • [7] Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents
    Miyata, Y
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) : 1131 - 1138
  • [8] Study of Hsp90α and Hsp90β role in virus replication using cell lines with Hsp90 gene knockouts
    Bieganowski, Pawel
    Dalidowska, Iga
    Gazi, Olga
    Guzowska, Magdalena
    Przybylski, Maciej
    VIRUS GENES, 2025, : 277 - 283
  • [9] The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
    Kaur, Jatinder
    Bhardwaj, Atul
    Melancon, Bruce J.
    Blagg, Brian S. J.
    SYNTHETIC COMMUNICATIONS, 2019, 49 (11) : 1436 - 1443
  • [10] Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities
    Lin, Shanshan
    Zhang, LingYu
    Zhang, Xiao
    Yu, Zelei
    Huang, Xiuwang
    Xu, Jianhua
    Liu, Yang
    Chen, Limin
    Wu, Lixian
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (09)